Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Gene Therapy Pioneer Launches New Biotech for Ultra-Rare Diseases

Gene Therapy Pioneer Launches New Biotech for Ultra-Rare Diseases

In a significant development for the gene therapy sector, renowned industry pioneer James Wilson, M.D., Ph.D., has unveiled a new clinical-stage spinout focused on ultra-orphan diseases. The company, Rare Therapeutics (RareTx), emerges from GEMMA Biotherapeutics with an ambitious mission to address some of the most challenging and underserved areas in genetic medicine.

NoahAI News10/8/2025
Atlantic Health and Saint Peter's Healthcare System Abandon Merger Plans Amid Shifting Healthcare Landscape

Atlantic Health and Saint Peter's Healthcare System Abandon Merger Plans Amid Shifting Healthcare Landscape

Atlantic Health System and Saint Peter's Healthcare System have called off their planned merger, citing the rapidly evolving healthcare landscape as the primary reason for terminating the combination. The decision marks a significant setback for both New Jersey-based nonprofit health systems and highlights the challenges facing healthcare mergers and acquisitions in the current economic and regulatory environment.

NoahAI News10/8/2025
FDA Shows Flexibility in Potential Accelerated Approval for Lexeo's Rare Disease Gene Therapy

FDA Shows Flexibility in Potential Accelerated Approval for Lexeo's Rare Disease Gene Therapy

Lexeo Therapeutics has announced a significant development in its pursuit of a gene therapy treatment for Friedreich's ataxia (FA) cardiomyopathy. The company revealed that the U.S. Food and Drug Administration (FDA) has indicated openness to an accelerated approval filing for LX2006, Lexeo's experimental gene therapy. This decision could potentially expedite the therapy's path to market, offering new hope for patients suffering from this rare and life-threatening condition.

NoahAI News10/8/2025
Encora Therapeutics Announces Leadership Change as FDA Review Continues

Encora Therapeutics Announces Leadership Change as FDA Review Continues

Encora Therapeutics, a Cambridge, Massachusetts-based medical device company specializing in wearable technology for movement disorders, has announced a significant leadership transition. The company, known for its innovative approach to treating essential tremors and Parkinson's disease, is positioning itself for potential FDA approval and commercial growth.

NoahAI News10/8/2025
Eli Lilly Calls for Urgent Improvements in Alzheimer's Diagnostic Testing Across Europe

Eli Lilly Calls for Urgent Improvements in Alzheimer's Diagnostic Testing Across Europe

Pharmaceutical giant Eli Lilly is spearheading a campaign for significant enhancements to Alzheimer's disease diagnostic testing practices throughout Europe. This initiative comes on the heels of the company's recent approval for its Alzheimer's therapy, Kisunla, in the European market.

NoahAI News10/8/2025
Boehringer Ingelheim's Jascayd Ushers in New Era for Idiopathic Pulmonary Fibrosis Treatment

Boehringer Ingelheim's Jascayd Ushers in New Era for Idiopathic Pulmonary Fibrosis Treatment

Boehringer Ingelheim has secured FDA approval for Jascayd (nerandomilast), marking the first new therapy for idiopathic pulmonary fibrosis (IPF) in over a decade. This breakthrough oral medication promises to reshape the landscape of IPF treatment, offering new hope for patients grappling with this progressive and often fatal lung disease.

NoahAI News10/8/2025
MapLight Therapeutics Aims for $262M IPO to Fund Schizophrenia and Alzheimer's Programs

MapLight Therapeutics Aims for $262M IPO to Fund Schizophrenia and Alzheimer's Programs

MapLight Therapeutics, a California-based biotech company, has unveiled plans for an initial public offering (IPO) that could raise up to $262 million. The company intends to use the proceeds to advance its pipeline, with a focus on developing treatments for schizophrenia and Alzheimer's disease psychosis.

NoahAI News10/8/2025
US Government Invests $48M in Kernal Bio's mRNA CAR-T Program

US Government Invests $48M in Kernal Bio's mRNA CAR-T Program

The U.S. government, through the Advanced Research Projects Agency for Health (ARPA-H), has awarded up to $48 million to Kernal Bio and three sub-awardees to advance the development of an innovative in vivo mRNA-encoded CAR T-cell program. This significant investment aims to push forward next-generation cell therapies for both cancer and autoimmune diseases.

NoahAI News10/8/2025
RNA Biotech Soufflé Therapeutics Rises with $200M Series A and Big Pharma Partnerships

RNA Biotech Soufflé Therapeutics Rises with $200M Series A and Big Pharma Partnerships

In a significant development for the RNA therapeutics field, Soufflé Therapeutics has emerged with a substantial $200 million series A funding round and partnerships with major pharmaceutical companies. The biotech startup, co-founded by Moderna pioneer Robert Langer, aims to develop targeted and cell-specific siRNA medicines.

NoahAI News10/8/2025
BioSpace Unveils Inaugural 40 Under 40 List, Highlighting Biotech and Pharma Innovation

BioSpace Unveils Inaugural 40 Under 40 List, Highlighting Biotech and Pharma Innovation

BioSpace has announced its first-ever 40 Under 40 list, recognizing outstanding young professionals in the biotech and pharmaceutical industries. The inaugural cohort showcases a diverse group of leaders who are driving innovation, shaping drug development, and making significant impacts on patient outcomes.

NoahAI News10/7/2025
OXB Expands US Presence with $4.5M Acquisition of Viral Vector Plant from National Resilience

OXB Expands US Presence with $4.5M Acquisition of Viral Vector Plant from National Resilience

Oxford Biomedica (OXB), a leading cell and gene therapy manufacturer, has taken a significant step in its US expansion strategy by acquiring a viral vector plant in North Carolina from National Resilience for $4.5 million (£3.4 million). This move comes less than two months after OXB announced a £60 million ($81 million) equity raise to support its growth plans in the United States.

NoahAI News10/7/2025
GLD Partners Launches Altagenics to Tackle Muscle-Wasting Conditions Using Heligenics' GigaAssay Platform

GLD Partners Launches Altagenics to Tackle Muscle-Wasting Conditions Using Heligenics' GigaAssay Platform

In a significant move to address unmet medical needs in muscle-wasting conditions, GLD Partners has announced the launch of Altagenics, a new biotech startup aimed at developing first-in-class medicines for sarcopenia and cachexia. The venture leverages Heligenics' cutting-edge GigaAssay platform, marking a strategic collaboration in the pharmaceutical industry's ongoing battle against age-related muscle loss and cancer-associated wasting syndromes.

NoahAI News10/7/2025
«1...505152...67»